Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $119.22

Ascendis Pharma A/S (NASDAQ:ASND) gapped up prior to trading on Monday . The stock had previously closed at $119.22, but opened at $139.65. Ascendis Pharma A/S shares last traded at $143.83, with a volume of 357,706 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ASND. TD Cowen reduced their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, September 5th. JPMorgan Chase & Co. reduced their target price on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Monday. Finally, Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They set a “buy” rating and a $200.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $187.08.

Ascendis Pharma A/S Stock Up 17.5 %

The stock has a market cap of $8.15 billion, a PE ratio of -14.97 and a beta of 0.63. The stock’s fifty day moving average price is $132.45 and its 200 day moving average price is $136.53.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of ASND. Private Ocean LLC purchased a new stake in shares of Ascendis Pharma A/S during the first quarter valued at $36,000. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Finally, Bessemer Group Inc. boosted its holdings in Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.